triple agonist therapy obesity

triple agonist therapy obesity

Expose Obesity Treatment Failure With Triple Agonists

More than 30% of patients on semaglutide or tirzepatide experience weight-loss plateaus within six months, signaling that single-agent GLP-1 therapy often runs out of steam. In my practice, I see these plateaus translate into less than 5% additional loss despite continued dosing, which forces clinicians to look beyond a lone